Curis Inc (CRIS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.00 (-8.26%), Market cap $0.02B, 52-week low–high $0.50 ~ $2.80.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-
Financial statements, price targets, institutional (13F) holdings and related news for Curis Inc are updated in real time on BlackAll Trade.
Curis Inc trades at $1.00 (-8.26%). Real-time quotes and charts are available on BlackAll Trade.
Curis Inc has a market cap of about $0.02B.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Em